<p>Women should avoid becoming pregnant while being treated with Bortezomib. Pregnant women should be apprised of the potential harm to the fetus<br />
<br />
Peripheral neuropathy, including severe cases, may occur - manage with dose modification or discontinuation. Patients with preexisting severe neuropathy should be treated with Bortezomib only after careful risk-benefit assessment.<br />
<br />
Hypotension can occur. Caution should be used when treating patients receiving antihypertensives, those with a history of syncope, and those who are dehydrated.&nbsp;<br />
<br />
Patients with risk factors for, or existing heart disease, should be closely monitored.<br />
<br />
Acute diffuse infiltrative pulmonary disease has been reported.<br />
<br />
Nausea, diarrhea, constipation, and vomiting have occurred and may require use of antiemetic and antidiarrheal medications or fluid replacement.<br />
<br />
Thrombocytopenia or neutropenia can occur; complete blood counts should be regularly monitored throughout treatment.<br />
<br />
Tumor Lysis Syndrome, Reversible Posterior Leukoencephalopathy Syndrome, and acute hepatic failure&nbsp;have been reported.</p>